Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product.
暂无分享,去创建一个
E. Gilboa | P. Dahm | A. Weizer | D. Boczkowski | J. Vieweg | V. Turaga | Z. Su | J. Higgins | J. Dannull | D. Yancey | Donna R. Yancey
[1] E. Gilboa,et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. , 2002, The Journal of clinical investigation.
[2] B. Armbruster,et al. N-Terminal Domains of the Human Telomerase Catalytic Subunit Required for Enzyme Activity in Vivo , 2001, Molecular and Cellular Biology.
[3] Michel C. Nussenzweig,et al. Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.
[4] A. Khanolkar,et al. Preferential utilization of the perforin/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblastoid cells by virus-specific CD4+ T cells. , 2001, Virology.
[5] E. Blackburn,et al. A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[6] R. Steinman,et al. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. , 2001, The Mount Sinai journal of medicine, New York.
[7] P. Dahm,et al. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. , 2001, Cancer research.
[8] M. Björkholm,et al. Real-time quantitative telomeric repeat amplification protocol assay for the detection of telomerase activity. , 2001, Clinical chemistry.
[9] D. Schendel,et al. The generation of LMP2a‐specific cytotoxic T lymphocytes for the treatment of patients with Epstein‐Barr virus‐positive Hodgkin disease , 2001, European journal of immunology.
[10] D. Weissman,et al. HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response1 , 2000, The Journal of Immunology.
[11] Eli Gilboa,et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. , 2000, Nature Medicine.
[12] K. Rock,et al. Characterization of MHC class II‐presented peptides generated from an antigen targeted to different endocytic compartments , 2000, European journal of immunology.
[13] E. Gilboa,et al. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. , 2000, Cancer research.
[14] A. Enk,et al. Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.
[15] C. Lowenstein,et al. The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.
[16] J. Shay,et al. Telomerase in cancer: diagnostic, prognostic, and therapeutic implications. , 1998, The cancer journal from Scientific American.
[17] E. Gilboa,et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA , 1998, Nature Biotechnology.
[18] C. Melief,et al. Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.
[19] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[20] J. Shay,et al. A survey of telomerase activity in human cancer. , 1997, European journal of cancer.
[21] R. Siliciano,et al. The Enhanced Immune Response to the HIV gp160/LAMP Chimeric Gene Product Targeted to the Lysosome Membrane Protein Trafficking Pathway* , 1997, The Journal of Biological Chemistry.
[22] R. Germain,et al. Processing and Presentation of Endocytically Acquired Protein Antigens by MHC Class II and Class I Molecules , 1996, Immunological reviews.
[23] Kathleen R. Cho,et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[24] R. Siliciano,et al. Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. , 1995, Journal of immunology.
[25] M. Bunce,et al. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. , 1995, Tissue antigens.
[26] C B Harley,et al. Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.
[27] R. Schreiber,et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. , 1994, Immunity.
[28] C. Peters,et al. Targeting of a lysosomal membrane protein: a tyrosine‐containing endocytosis signal in the cytoplasmic tail of lysosomal acid phosphatase is necessary and sufficient for targeting to lysosomes. , 1990, The EMBO journal.
[29] K. von Figura,et al. The tyrosine motifs of Lamp 1 and LAP determine their direct and indirect targetting to lysosomes. , 2002, Journal of cell science.
[30] T. Wu,et al. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene , 2001, Gene Therapy.
[31] F. Guarnieri,et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.